

## IN THE CLAIMS

✓  
Please amend claims 1 and 4, as follows, with a marked up copy of the amended claims being included in an Appendix attached thereto:

B<sup>1</sup>  
1. (Amended) An oral formulation for gastrointestinal drug delivery which comprises an adhesion site-controlling layer for attaching the formulation to a selected site in the digestive tract, a drug-carrying layer for containing a drug and an adhesive and a protecting layer for protecting the drug in the drug-carrying layer, wherein the drug-carrying layer exists between the protecting layer and the adhesion site-controlling layer, and the adhesion site-controlling layer may attach to the protecting layer. 3 layers

B<sup>2</sup>  
4. (Amended) The oral formulation for gastrointestinal drug delivery according to claim 1 wherein the protecting layer is in hemispherical form forming an inner space and an opening part, and the drug-carrying layer exists in the inner space of the protecting layer in said hemispherical form, and wherein the adhesion site-controlling layer covers the opening part of the protecting layer in said hemispherical form.

✓  
Please add claims as follows:

B<sup>3</sup>  
22. (New) The oral formulation for gastrointestinal drug delivery according to claim 1 wherein the adhesion site-controlling layer is attached to the protecting layer.

23. (New) The oral formulation for gastrointestinal drug delivery according to claim 1 wherein the drug-carrying layer is sealed between the adhesion site-controlling layer and the protecting layer to prevent leaking of the drug.